WX
WuXi Biologics (Cayman) Inc.
WXIBF · OTC
$6.23 +0.00% (+$0.00)
1M +6.50%
Market Cap ¥172.8B
P/E Ratio 36.14x
Div. Yield -
ROE 10.50%
Bulios Fair Price
$4.19
32.7% downside
Current Price
$6.23
Undervalued Fair Value Overvalued
According to Bulios Fair Price, WXIBF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
9/9Valuation
24 /100
Expensive PEG 0.85x
P/S 8.14x
P/B 3.66x
Growth
60 /100
Stable Rev. growth 11.61%
Book val. growth 10.49%
EPS growth 3.51%
Profitability
92 /100
Strong Net margin 22.53%
Op. margin 30.50%
FCF margin 13.19%
Quality
49 /100
Average ROE 10.50%
ROA 7.50%
Asset turnover 0.33x
Debt
100 /100
Low Current ratio 3.14x
Int. coverage 46.46x
Net debt/EBITDA -0.75x
Stability
88 /100
Stable Rev. volatility 2.02%
EPS volatility 34.04%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about WXIBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Zhisheng Chen
Employees
13,252
Headquarters
Wuxi
Upcoming events
23 MAR
Earnings
Upcoming earnings report